CR 3700
Latest Information Update: 25 Feb 2010
Price :
$50 *
At a glance
- Originator Rottapharm
- Class Antispasmodics; Irritable bowel syndrome therapies
- Mechanism of Action Cholecystokinin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gastro-oesophageal reflux; Irritable bowel syndrome; Pancreatitis
Most Recent Events
- 07 Aug 2003 Preclinical trials in Gastro-oesophageal reflux in Italy (unspecified route)
- 07 Aug 2003 Preclinical trials in Irritable bowel syndrome in Italy (unspecified route)
- 07 Aug 2003 Preclinical trials in Pancreatitis in Italy (unspecified route)